U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07455045) titled 'A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)' on March 02.
Brief Summary: An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especially in DMG and other Recurrent HGG.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
High Grade Glioma (III or IV)
Diffuse Midline Glioma (DMG)
Glioblastoma (GBM)
Intervention:
DRUG: FZ-AD005
Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal...